

IMMUNOGEN

ImmunoGen, Inc.
Investor Relations Department
830 Winter Street
Waltham, MA 02451
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: IMGN

Last Trade:	6.15
Trade Time:	4:00 PM ET Nov 17, 2017
Change:	0.00 (0.000%)
Day Range	5.89 - 6.15
52-Week Range	1.53 - 8.84
Volume	3,176,400

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roc... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Nov 7, 2017

[ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences](#)

Nov 3, 2017

[ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results](#)

Nov 1, 2017

[ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 59th ASH Annual Meeting](#)

Oct 20, 2017

[ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2017 Financial Results](#)

Oct 16, 2017

[ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active](#)

Upcoming Events [\[View all \]](#)

Nov 30, 2017 1:15 PM ET

[Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)